Trials / Completed
CompletedNCT01933516
GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma
Phase I Trial to Assess the Safety and Pharmacokinetics of GP2013 Monotherapy Administered Weekly in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Sandoz · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety and pharmacokinetic of GP2013 in Japanese patients with CD20 positive low tumor burden indolent B-cell NHL under weekly dosing schedule.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GP2013 | GP2013 |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2013-09-02
- Last updated
- 2018-07-26
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01933516. Inclusion in this directory is not an endorsement.